Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer

Journal of the National Cancer Institute

Volumn 90, Issue 9, 1998, Pages 704-708

  Powles, Trevor J ^a   McCloskey, Eugene ^b   Paterson, Alexander H G ^c   Ashley, Susan ^a   Tidy, V Alwynne ^a   Nevantaus, Auli ^a   Rosenqvist, Kirsi ^d   Kanis, John ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF CALGARY   (Canada)

^d Oy Leiras Finland Ab   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; PLACEBO; TAMOXIFEN;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BONE DENSITY; BONE MINERAL; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HIP; HOT FLUSH; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE;

EID: 0032490125     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.9.704     Document Type: Article

References (17)

1. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A, et al. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990;61:308-10.
2. Poilles JM, Tremollieres F, Bonneu M, Ribot C. Influence of early age at menopause on vertebral bone mass. J Bone Miner Res 1994;9: 311-15.
3. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
4. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996;14: 78-84.
5. Oestrogens for HRT. In: Mehta D, editor. British national formulary. Vol 33. Oxford: Pharmaceutical Press, 1997:310.
6. Marsden J, Sacks N. Hormone replacement therapy for the breast cancer survivor. J Endocrinol 1996;3:81-97.
7. DiSaia P. Estrogen replacement therapy for the breast cancer survivor. J Soc Gynaecol Investig 1996;3:57-9.
8. Urwin GH, Yates AJ, Gray RE, Hamdy NA, McCloskey EV, Preston FE, et al. Treatment of the hypercalcemia of malignancy with intravenous clodronate. Bone 1987;8 Suppl1:S43-51.
9. Paterson AH, Powles TJ, Kanis JA, McCloskey EV, Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastates from breast cancer. J Clin Oncol 1993;11:59-65.
10. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastates in women with breast cancer. Bone 1996;19:663-7.
11. Giannini S, D'Angelo A, Malvisi L, Castrignano R, Pati T, Tronca R, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone 1993;14: 137-41.
12. Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, et al. Cyclic clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res 1995;10:697-703.
13. Liberman UA, Weiss SR, Broil J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Study Group. N Engl J Med 1995;333: 1437-43.
14. International Union Against Cancer. TNM Classification. London: Springer. 1997:204.
15. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antioestrogens. Brit J Cancer 1997;75:602-5.
16. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorrouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997;15: 1341-7.
17. Delmas PD, Balena R, Contravreux E, Hardouin C, Hardy P, Bremond A. Biphosphate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997;15: 955-62.